Cargando…

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection

IMPORTANCE: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, testing for albuminuria among patients with T2D is substantially underutilized in clinical practice; many...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michos, Erin D., Bakris, George L., Rodbard, Helena W., Tuttle, Katherine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	State-of-the-Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258236/ https://www.ncbi.nlm.nih.gov/pubmed/37313358 http://dx.doi.org/10.1016/j.ajpc.2023.100502

Ejemplares similares

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)

Hyperuricemia, the heart, and the kidneys – to treat or not to treat?
por: Petreski, Tadej, et al.
Publicado: (2020)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Estrogen and estrogen receptors in kidney diseases
por: Ma, Hao-Yang, et al.
Publicado: (2021)

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
por: Rossing, Peter, et al.
Publicado: (2022)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

In Reply to ‘Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?’
por: Leehey, David J.
Publicado: (2021)

Acute toxic kidney injury
por: Petejova, Nadezda, et al.
Publicado: (2019)

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
por: Michos, Erin D., et al.
Publicado: (2023)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
por: Elder, Petal, et al.
Publicado: (2020)

Advance of autophagy in chronic kidney diseases
por: Deng, Xu, et al.
Publicado: (2017)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Targeting Vascular Calcification in Chronic Kidney Disease
por: Nelson, Adam J., et al.
Publicado: (2020)

Therapeutic apheresis in kidney diseases: an updated review
por: Chen, Yi-Yuan, et al.
Publicado: (2022)

The role of kidney injury biomarkers in COVID-19
por: Su, Lianjiu, et al.
Publicado: (2022)

Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)

Advances in imaging techniques to assess kidney fibrosis
por: Jiang, Buchun, et al.
Publicado: (2023)

Regulatory RNAs in Heart Failure
por: Gomes, Clarissa Pedrosa da Costa, et al.
Publicado: (2020)

Calcium Buffering in the Heart in Health and Disease
por: Smith, Godfrey L., et al.
Publicado: (2019)

Lipids, blood pressure, kidney – what was new in 2011?
por: Barylski, Marcin, et al.
Publicado: (2011)

Biomarker for early renal microvascular and diabetic kidney diseases
por: Futrakul, Narisa, et al.
Publicado: (2017)

A long journey for acute kidney injury biomarkers
por: Oh, Dong-Jin
Publicado: (2020)

The research status and prospect of Periostin in chronic kidney disease
por: Jia, Yuan-yuan, et al.
Publicado: (2020)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Breath of Life: Heart Disease Link to Developmental Hypoxia
por: Giussani, Dino A.
Publicado: (2021)

Acquired long QT syndrome in chronic kidney disease patients
por: Liu, Peng, et al.
Publicado: (2019)

Protective and damaging effects of stress mediators: central role of the brain
por: McEwen, Bruce S.
Publicado: (2006)

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
por: Liljedahl, Leena, et al.
Publicado: (2019)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease
por: Li, Ran, et al.
Publicado: (2022)

Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients
por: Kim, Min Kyung, et al.
Publicado: (2021)

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
por: Lin, Yuan, et al.
Publicado: (2023)

Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression
por: Duman, Ronald S.
Publicado: (2009)

Wasp venom-induced acute kidney injury: current progress and prospects
por: Yu, Fanglin, et al.
Publicado: (2023)

The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease’s ‘ABC’s Approach
por: Feldman, David I., et al.
Publicado: (2020)

Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update
por: Ying, Qidi, et al.
Publicado: (2017)

Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney
por: Simeoni, Mariadelina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_30ak9h23ttspc92roeo6tusrij